SCHEMBL22327159

SCHEMBL22327159

CNCCCOCCOCCOCCNC(=O)c1cccc(OCC(C)C)c1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.55
▸ GAA P10253 1/20 0.55
▸ NR1H4 Q96RI1 1/20 0.51
▸ ALDH1A1 P00352 3/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ NSD2 O96028 1/20 0.49
▸ KAT6A Q92794 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ F10 P00742 2/20 0.47
▸ MAOB P27338 1/20 0.47
▸ POLB P06746 1/20 0.46
▸ NPC1 O15118 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22327399 0.91 GAA (0.54) MAPTGAAALDH1A1SMN1; SMN2KDM4E
SCHEMBL22219850 0.90 MAPT (0.54) MAPTGAANR1H4ALDH1A1SMN1; SMN2
SCHEMBL22598297 0.89 MAPT (0.55) MAPTGAANR1H4ALDH1A1SMN1; SMN2
SCHEMBL24023147 0.89 GAA (0.55) MAPTGAAALDH1A1SMN1; SMN2KDM4E
SCHEMBL26168403 0.88 GAA (0.61) MAPTGAANR1H4ALDH1A1SMN1; SMN2
SCHEMBL22219831 0.88 SMN1; SMN2 (0.58) MAPTGAAALDH1A1SMN1; SMN2KDM4E
SCHEMBL26068727 0.88 GAA (0.53) MAPTGAANR1H4ALDH1A1SMN1; SMN2
SCHEMBL24002288 0.87 NR1H4 (0.53) MAPTGAANR1H4ALDH1A1SMN1; SMN2
SCHEMBL24023148 0.86 NR1H4 (0.59) MAPTGAANR1H4ALDH1A1KAT6A
SCHEMBL22219742 0.86 NR1H4 (0.52) MAPTGAANR1H4ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257414-A1 NUCLEOTIDE ANALOGUES FIRST-CITIZENS BANK & TRUST COMPANY 2023-08-17 — — US disclosed
US-20230203083-A1 NUCLEOTIDE ANALOGUES FIRST-CITIZENS BANK & TRUST COMPANY 2023-06-29 — — US disclosed
US-20230160001-A1 NUCLEOTIDE CLEAVABLE LINKERS WITH RIGID SPACERS AND USES THEREOF FIRST-CITIZENS BANK & TRUST COMPANY 2023-05-25 — — US disclosed
US-20230028359-A1 NUCLEOTIDE ANALOGUES FIRST-CITIZENS BANK & TRUST COMPANY 2023-01-26 — — US disclosed
US-20230002436-A1 MODIFIED NUCLEOTIDES AND USES THEREOF FIRST-CITIZENS BANK & TRUST COMPANY 2023-01-05 — — US disclosed
US-20220127299-A1 NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF LG ELECTRONICS INC. (KR) 2022-04-28 — — US disclosed
US-11174281-B1 Modified nucleotides and uses thereof Singular Genomics Systems, Inc. (US) 2021-11-16 — — US disclosed
US-10822653-B1 Nucleotide cleavable linkers and uses thereof Singular Genomics Systems, Inc. (US) 2020-11-03 — — US disclosed
US-20200340051-A1 NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF FIRST-CITIZENS BANK & TRUST COMPANY 2020-10-29 — — US disclosed
US-10738072-B1 Nucleotide analogues Singular Genomics Systems, Inc. (US) 2020-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200340051-A1 NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF NUDT21, CPSF7, DCLRE1A MAPT 3729/4885GAA 678/4885NR1H4 4066/4885
US-20230002436-A1 MODIFIED NUCLEOTIDES AND USES THEREOF NUDT1, RNMT, ADAR MAPT 4693/4885GAA 668/4885NR1H4 4394/4885
US-20220127299-A1 NUCLEOTIDE CLEAVABLE LINKERS AND USES THEREOF NUDT21, CPSF7, DCLRE1A MAPT 3729/4885GAA 678/4885NR1H4 4066/4885
US-20230257414-A1 NUCLEOTIDE ANALOGUES ITPA, POLB, NUDT1 MAPT 4328/4885GAA 1026/4885NR1H4 3934/4885
US-11174281-B1 Modified nucleotides and uses thereof NUDT1, RNMT, ADAR MAPT 4693/4885GAA 668/4885NR1H4 4394/4885
US-10822653-B1 Nucleotide cleavable linkers and uses thereof NUDT21, CPSF7, DCLRE1A MAPT 3729/4885GAA 678/4885NR1H4 4066/4885
US-20230028359-A1 NUCLEOTIDE ANALOGUES ITPA, POLB, NUDT1 MAPT 4328/4885GAA 1026/4885NR1H4 3934/4885
US-10738072-B1 Nucleotide analogues NUDT1, POLN, TYMP MAPT 4520/4885GAA 759/4885NR1H4 2418/4885
US-20230203083-A1 NUCLEOTIDE ANALOGUES ITPA, POLB, NUDT1 MAPT 4328/4885GAA 1026/4885NR1H4 3934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback